0.00 2024 INTERIM REPORT 2024 2024 中期報告 INTERIM REPORT 中期報告 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微创医疗机器人（集团）股份有限公司 the state and the first Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微创医疗机器人（集团）股份有限公司 (a joint stock company incorporated in People's Republic of China with limited liability) 股票代碼：2252 Stock Code: 2252 （於中華人民共和國註冊成立的股份有限公司） 2252 （於中華人民共和國註冊成立的股份有限公司） 目 錄 2 公司資料 4 財務摘要 5 公司概況 6 總裁報告 9 管理層討論及分析 31 企業管治及其他資料 42 獨立核數師報告 43 綜合損益表 44 綜合損益及其他全面收益表 45 綜合財務狀況表 47 綜合權益變動表 49 簡明綜合現金流量表 50 未經審計 ...

[ T able_StockInfo] 2024 年 09 月 04 日 证券研究报告•2024 年中报点评 当前价：6.55 港元 微创机器人-B（2252.HK）医疗保健 目标价：——港元 海外订单达 10 台，国产机器人迎出海里程碑 [Table_Summary 事件：公司发布] 2024中报，实现营业收入 1.0亿元（+106%），毛利 4701万 元，净亏损 2800 万元，亏损明显收窄主要因： 1）营业收入增长；2）业务聚 焦和降本增效带来的费用优化。 强化腔镜和骨科机器人的业务聚焦，国内海外双点开花。（1）腔镜手术机器人 图迈：截至 24H1，公司自研腔镜机器人"图迈"已在国内 20 家医院实现商业 化装机，辅助完成人体临床手术量突破 1300例，位居国产腔镜机器人第一。海 外端，图迈海外在手订单量累计达 10台，已有 2台实现商业化装机，是国产腔 镜手术机器人出海的标志性里程碑。（2）骨科手术机器人：截至 24H1，骨科 手术机器人鸿鹄已累计获得约30台海外销售订单，全球累计 TKA手术量超1300 例，覆盖约 70家医院。 降本增效是主旋律。24H1公司净亏损 2800万元，同比缩窄 48. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2024年6月30日止六個月之中期業績公告 董事會欣然公佈本集團截至2024年6月30日止六個月之未經審核綜合中期業績， 連同截至2023年6月30日止六個月之比較數字，已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（倘文意另有所指）本集團。本公 告所載若干金額及百分比數據已因約整進行調整，或已約整至一個或兩個小 數位。任何表格、圖表或其他地方中總額與當中所列金額總和之間的任何差異 乃因約整所致。 | --- | --- | --- | |---------------------------------------|--------------------------------- ...

Financial Performance - Revenue for 2023 reached RMB 104,592 thousand, a significant increase from RMB 21,603 thousand in 2022[8] - Gross profit for 2023 was RMB 14,694 thousand, up from RMB 6,562 thousand in 2022[8] - The company reported a net loss of RMB 1,023,530 thousand in 2023, compared to a net loss of RMB 1,146,284 thousand in 2022[8] - Total assets decreased to RMB 1,427,907 thousand in 2023 from RMB 1,930,125 thousand in 2022[9] - Non-current assets stood at RMB 633,859 thousand in 2023, down from RMB 831,303 thousand in 2022[9] - Current liabilities increased to RMB 685,276 thousand in 2023 from RMB 325,314 thousand in 2022[9] - The company's free cash flow net outflow decreased by 42% from RMB 1,158 million in 2022 to RMB 670 million in 2023[18] - Revenue for the year ended December 31, 2023, was RMB 104.6 million, a 384.2% increase from RMB 21.6 million in 2022, driven by strong market performance of the core product Toumai and successful overseas promotion of orthopedic robots[61] - Gross profit increased by 123.9% to RMB 14.7 million in 2023 from RMB 6.6 million in 2022, but gross margin decreased to 14% from 30% due to inventory impairment of RMB 29.0 million[62] - Sales and marketing expenses rose by 29.6% to RMB 238.4 million in 2023 from RMB 184.0 million in 2022, primarily due to increased commercialization efforts and marketing team costs[63] - Administrative expenses decreased by 25.9% to RMB 126.4 million in 2023 from RMB 170.5 million in 2022, mainly due to optimization of operational efficiency and reduced staffing costs[64] - R&D costs decreased by 24.7% to RMB 569.2 million in 2023 from RMB 755.8 million in 2022, as the company focused on products nearing commercialization and improved R&D efficiency[65] - Other net loss was RMB 13.3 million in 2023, compared to a net income of RMB 42.1 million in 2022, primarily due to RMB 40.5 million in losses from site lease terminations[67] - Net loss on financial instruments at fair value through profit or loss was RMB 42.5 million in 2023, compared to RMB 27.0 million in 2022, mainly due to a further decline in the fair value of NDR investment[68] - Financing costs increased to RMB 18.6 million in 2023 from RMB 11.4 million in 2022, primarily due to higher bank loan interest[69] - Inventory as of December 31, 2023, was RMB 229.5 million, with an inventory impairment of RMB 29.0 million due to product upgrades and optimization[73] - Capital expenditures for the reporting period were RMB 66.5 million, primarily for property, plant, and equipment[75] - Employee costs decreased to RMB 561.2 million in 2023 from RMB 612.9 million in 2022, primarily due to a reduction in the number of employees[76] - Cash and cash equivalents decreased to RMB 507.7 million as of December 31, 2023, from RMB 748.0 million as of December 31, 2022, driven by increased R&D and marketing activities[77] - Total interest-bearing borrowings increased to RMB 475.1 million as of December 31, 2023, compared to RMB 33.1 million as of December 31, 2022, with the debt-to-asset ratio rising to 65% from 27%[80] - Net current assets decreased to RMB 108.8 million as of December 31, 2023, from RMB 773.5 million as of December 31, 2022, due to ongoing R&D, clinical registration, and commercialization expenses[81] Product Development and Commercialization - Core product TuMai completed 10 commercial installations during the reporting period, achieving strong year-on-year growth[14] - TuMai has secured nearly 20 bids nationwide, breaking the long-term market monopoly of imported brands and leading the domestic market share[14] - The company's Mona Lisa prostate biopsy robot achieved 1 commercial installation after receiving NMPA approval in May 2023[14] - R-ONE vascular intervention robot accumulated several intention orders shortly after its approval in December 2023, showing strong commercialization potential[14] - TuMai secured its first overseas order at the end of 2023, marking a significant milestone for domestic surgical robots in international markets[15] - The company's Honghu robot has accumulated 15 overseas sales orders and completed over 100 robot-assisted surgeries[15] - The company obtained 8 domestic and international registrations/approvals in 2023, including NMPA approvals for TuMai, Honghu, R-ONE, and Mona Lisa[16] - TuMai has completed over 120 5G remote clinical surgeries globally with a 100% success rate[17] - The company's revenue in 2023 reached RMB 104.6 million, a strong increase of 384.2% compared to the previous year's RMB 21.6 million, driven by the commercialization of its main products, including Toumai, Honghu, and Qingtingyan[22] - Toumai, the company's core product, completed 10 commercial installations in 2023, a significant increase from the previous year, and has accumulated nearly 20 bids nationwide, including top-tier hospitals[23] - The company's Mona Lisa prostate biopsy robot achieved 1 commercial installation and successfully performed 1 commercial surgery after receiving NMPA approval in May 2023[23] - The R-ONE vascular intervention robot, approved in December 2023, has quickly accumulated several intent orders, showing strong commercialization potential[23] - The company's products, including Toumai, Honghu, and Qingtingyan, have maintained their leading positions in their respective fields despite intense domestic competition[23] - The company's international cooperation in the field of percutaneous surgery has led to the development of the Mona Lisa prostate biopsy robot, which has shown promising results in the market[23] - The company's focus on technological innovation and commercialization has been a key driver of its revenue growth[22] - The company's products have been recognized for their clinical value, technological innovation, and comprehensive training services, earning the trust of doctors and hospitals[23] - The company's strategic focus on sustainable growth and operational efficiency has helped it navigate the challenges of a complex global economic and geopolitical environment[22] - The company's products have been instrumental in advancing the adoption of robotic-assisted surgery in China, contributing to the overall growth of the surgical robot market[19] - Tuo Mai achieved its first overseas sales order, marking the first overseas sale of a domestically produced laparoscopic surgical robot, and successfully assisted in its first overseas radical prostatectomy[24] - Hong Hu, the company's flagship product, has accumulated 15 overseas sales orders and completed over 100 robot-assisted surgeries, including multiple consecutive surgeries[24] - Tuo Mai has completed over 120 5G remote clinical surgeries globally with a 100% success rate, setting nearly 20 national and global remote surgery records[27] - The company's free cash flow outflow decreased by 42% from RMB 1,158 million in 2022 to RMB 670 million in 2023 due to strategic focus and cost reduction measures[28] - Tuo Mai received NMPA approval in October 2023 for multi-department commercialization, including urology, general surgery, gynecology, and thoracic surgery[26] - Hong Hu received approvals from Brazil ANVISA, Australia TGA, and UK UKCA, becoming the first and only domestic surgical robot approved in major markets including China, the US, EU, Brazil, Australia, and the UK[26] - R-ONE vascular intervention robot received NMPA approval in December 2023, becoming the first commercialized coronary vascular intervention robot in China[27] - iSR'obot Mona Lisa prostate biopsy robot received NMPA approval in May 2023, forming a diagnostic and therapeutic integration platform with Tuo Mai[27] - The company has accelerated the transformation of its five major business segments, with 4/5 segments having innovative products approved for market[26] - The company is the only surgical robot company globally covering five "golden tracks": laparoscopic, orthopedic, pan-vascular, natural orifice, and percutaneous surgery[29] - The company's core product, the Toumai laparoscopic surgical robot, has been approved for use in urology, general surgery, gynecology, and thoracic surgery by the NMPA in October 2023, significantly accelerating its commercialization process[33] - As of the report date, Toumai has secured nearly 20 domestic bids and completed 11 commercial installations, with 10 installations completed within 2023 alone[33] - Toumai has assisted in over 2,000 high-difficulty clinical surgeries across more than 90 hospitals in 31 provinces, including over 1,600 Level 4 surgeries and nearly 300 types of procedures[34] - Toumai has achieved over 120 successful 5G remote clinical surgeries globally, with a 100% success rate, including the longest-distance surgery spanning over 5,000 kilometers[37] - In December 2023, Toumai completed its first overseas commercial installation and successfully assisted in its first international clinical surgery for prostate cancer, marking a significant milestone for domestic laparoscopic surgical robots[36] - The company has established over 30 Toumai clinical application and training centers nationwide, enhancing its market presence and surgeon training capabilities[34] - Toumai's EU CE certification application has been accepted, and its remote endoscopic surgery system has initiated NMPA registration clinical work with clinical enrollment underway[37] - The company has made breakthroughs in 5G remote surgery technology, including the first transatlantic and transpacific remote surgery validations, showcasing its advanced capabilities in remote surgery[37] - Toumai has gained international recognition and influence, particularly after its debut at the 2023 SRS Annual Meeting, where it showcased its clinical and technical expertise[36] - The company has completed nearly 50 "first domestic cases" with Toumai, further solidifying its leading position in the domestic laparoscopic surgical robot market[34] - The Toumai single-arm laparoscopic surgical robot has completed enrollment for registration clinical trials and is being applied in multiple departments such as gynecology, urology, and general surgery in hospitals in Beijing, Shanghai, and Nanchang[39] - The Dragonfly three-dimensional electronic laparoscopic endoscope achieved stable sales performance during the reporting period and maintained its leading position among domestic brands[40] - The Dragonfly endoscope obtained the EU certification from the British Standards Institution (BSI) and expanded its market space in the high-end medical equipment field, laying a solid foundation for overseas commercialization[40] - The Honghu orthopedic surgical robot obtained NMPA approval for both total knee and total hip replacement surgeries, making it the first and only domestic robot with a self-developed robotic arm approved for such applications[41] - The Honghu robot has received FDA 510(k) certification, EU CE certification, Brazil ANVISA, Australia TGA, and UK UKCA certification, making it the first and only domestic surgical robot approved in major markets including China, the US, the EU, Brazil, Australia, and the UK[41] - The Honghu robot has accumulated 15 overseas orders and completed over 100 robot-assisted surgeries overseas[42] - The company has established nearly 20 Honghu clinical application and training centers nationwide and completed nearly 900 robot-assisted clinical validation surgeries in over 50 hospitals across 17 provinces and municipalities in China[42] - The Honghu robot has successfully conducted several 5G remote joint replacement surgeries, including the first 5G remote domestic robot-assisted total knee replacement surgery in Tibet[42] - The company expects the combined application of the Honghu robot and MicroPort's joint prostheses to effectively shorten the learning curve for doctors and maximize the clinical value of both products[42] - Honghu robot demonstrated high surgical precision and efficiency in total knee arthroplasty, with no significant difference compared to international top-tier orthopedic surgical robots[43] - Honghu completed its first human surgery for unicompartmental knee arthroplasty, marking its entry into clinical validation for such applications[44] - The bronchoscopic surgical robot successfully completed the first human clinical trial for robot-assisted bronchoscopic lung nodule biopsy in China[45] - R-ONE vascular intervention robot received NMPA approval in December 2023 and accumulated several domestic orders, with successful 5G-assisted remote PCI surgeries over 2,800 km[46][47] - Mona Lisa prostate biopsy robot achieved NMPA approval, completed one commercial installation, and performed one commercial surgery, filling a market gap in China[48] - The company's 5G remote surgery technology has achieved over 120 successful clinical cases globally, with a maximum transmission distance of 5,000 km and control distance of nearly 13,000 km[49] - The company has established over 30 Toumai clinical application and training centers and nearly 20 Honghu clinical application and training centers nationwide[52] - The company has applied for a total of 1,278 patents globally, with 395 patents granted (263 in China and 132 overseas)[56] - The company has two production bases in China, located in Shanghai and Suzhou, supporting large-scale production of surgical robots and consumables[54] - The company has built a mobile training and demonstration platform for surgical robots, promoting the technology nationwide[53] - The company has established two R&D centers in China (Shanghai and Shenzhen) and overseas R&D centers in Singapore and the U.S.[51] - The company has a team of approximately 650 employees, primarily based in China, Singapore, and the U.S.[55] - The company plans to expand its product portfolio and establish a multi-specialty surgical robot platform[58] - The company aims to accelerate commercialization and increase market penetration by establishing more training centers and improving clinical application experiences[59] - The company has partnered with 301 Hospital to build the world's first 5G remote precision minimally invasive surgery training center[50] - The company's Shanghai Minimally Invasive Surgical Robot Engineering Technology Research Center is the first provincial-level surgical robot engineering center[51] Corporate Governance and Leadership - Dr. He Chao, aged 39, was appointed as an Executive Director on October 18, 2017, and transferred to the role on June 10, 2022. He is responsible for overseeing the company's R&D, daily management, and strategic development[85] - Dr. He Chao has over 16 years of experience in surgical robotics R&D and holds multiple leadership roles within the company, including Executive Director of Suzhou MicroPort Changxing Robotics Co., Ltd. since July 2019[85] - Mr. Sun Hongbin, aged 49, was appointed as a Non-Executive Director on April 3, 2020, and transferred to the role on June 10, 2021. He serves as the Chairman of the Board and oversees the company's management and operations[86] - Mr. Sun Hongbin has over 20 years of experience in the medical device industry and currently serves as the CFO of MicroPort Medical Group and holds various executive roles within the group[86] - Mr. Chen Xinxing, aged 38, was appointed as a Non-Executive Director on December 29, 2023, and is responsible for overseeing the company's management and operations[87] - Mr. Chen Xinxing has extensive experience in investment banking and private equity, currently serving as Managing Director at Hillhouse Investment and Non-Executive Director at Ningbo Jenscare Biotechnology Co., Ltd[87] - Mr. Chen Chen, aged 40, was appointed as a Non-Executive Director on September 17, 2020, and transferred to the role on June 10, 2021. He oversees the company's management and operations[88] - Mr. Chen Chen has 12 years of experience in business consulting and investment management, currently serving as Executive General Manager at Beijing Panmao Investment Management Co., Ltd[88] - Dr. Li Minghua, aged 72, was appointed as an Independent Non-Executive Director on December 30, 2020, and transferred to the role on June 10, 2021. He chairs the Remuneration and Assessment Committee and is a member of the Audit and Strategic Development Committees[89] - Dr. Li Minghua has a distinguished career in radiology and medical imaging, having served as Director of the Radiology Department at Shanghai Sixth People's Hospital and Professor at Shanghai Jiao Tong University[89] - Yao Haisong, aged 50, was appointed as an independent director on December 30, 2020, and re-designated as an independent non-executive director on June 10, 2021[90] - Mei Yongkang, aged 52, was appointed as an independent non-executive director on June 21, 2022, and has over 25 years of experience in managing various financing and accounting activities[90] - Zhang Jie, aged 45, was appointed as a shareholder representative supervisor on December 30, 2020, and currently serves as the chairman of the supervisory board[92] - Zhang Lihong, aged 47, was appointed as a shareholder representative supervisor on December 30, 2020, and has extensive experience in intellectual property management[92] - Chen Gong, aged 32, was appointed as an employee representative supervisor on December 29, 2023, and has been responsible for the R&D management of surgical robots since January 2020[94] - Yao Haisong holds a Bachelor's degree in Clinical Medicine from Shanghai Second Medical University and a Master's degree in International Business Law from the National University of Singapore[90] - Mei Yongkang holds a Bachelor's degree in Business Administration from the Chinese University of Hong Kong and completed the CFO program at CEIBS[90] - Zhang Jie holds a Bachelor's degree in Communication Principles from Zhejiang University of Technology and a Master's degree in Testing and Measurement Technology from Shanghai University of Technology[92] - Zhang Lihong holds a Bachelor's degree in Detection Technology and Instruments from Xi'an University of Technology and a Master's degree in Measurement and Control Technology from Xi'an University of Technology[94] - Chen Gong holds a Bachelor's degree in Mechanical Design and Manufacturing from Henan University of Engineering and a Master's degree in Mechanical Engineering from Jiangsu University[94] - The company's board of directors and supervisors were re-elected and appointed on December 29, 2023, with Dr. He Chao re-elected as an executive director and Mr. Sun Hongbin re-elected as the chairman of the board[115] - The company's senior management compensation for the year ended December 31, 2023, includes one individual earning between RMB 1,000,001 and RMB 1,500,000, two individuals earning

[ 2T 0a 2b 4l 年e_S 0t 4o 月ckI 0n 3f 日o] 证券研究报告•2023年年报点评 当前价： 12.72港元 微创机器人-B（2252.HK） 医疗保健 目标价： ——港元 机器人智能手术全解方案布局趋于完善 投资要点 西南证券研究发展中心 [T ab事le件_S：u公m司ma发ry布] 2023年年报，实现营业收入1.0亿元（+384.2%），毛利1469 [分Ta析bl师e_：Au杜th向or阳] 万元，净亏损 10.2 亿元。营业收入实现显著增长主要因：1）公司核心产品图 执业证号：S1250520030002 迈多科室适应症获批后市场表现强劲；2）骨科机器人鸿鹄在海外市场的成功推 电话：021-68416017 广。2023年毛利率下降至14%（-16.4pp）主要因存货减值影响。2023年与去 邮箱：duxy@swsc.com.cn 年同期相比亏损减少主要因为 1）营业收入增长；2）聚焦核心研发项目带来研 发费用下降，3）降本增效措施成功实施。 [相Tab对le指_Q数u表ot现eP ic]  腔镜手术机器人图迈：商业化进展顺利，引领全球 5G远程手术探索。公司图迈 ...

浦银国际研究 公司研究 | 医药行业 微创机器人（2252.HK）：配置证下发有望提 速，重点关注公司后续资金规划 胡泽宇，CFA 浦 医药分析师 银 2023 年收入同比+384%至人民币 1.05 亿元（其中图迈确认 10 台装机 ryan_hu@spdbi.com 国 收入），归母净亏损同比缩减 11%至亏损人民币 10.1 亿元。随着“十 (852) 2808 6446 际 四五”进入下半程，我们预计配置证下发速度将逐步加快，叠加近期 设备更新方案的出台，或可抵消部分反腐下医院对大型设备采购相对 阳景 谨慎的潜在影响。考虑上尚未使用的授信额度，公司可动用现金仍不 宽裕，短期重点关注后续资金规划。下调目标价至 15.1港元。 首席医药分析师 Jing_yang@spdbi.com 2023业绩&2024指引：全年收入人民币1.05亿元（同比+384%），基  (852) 2808 6434 本符合市场预期。2023 年确认 10 台图迈装机收入，截至 2023 年末， 公 图迈累计中标18台，累计完成商业化装机11台；毛利率14.0%（同比 司 2024年4月3日 -16.3pcts），毛利率下降幅度 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2023年12月31日止年度 全年業績公告 董事會欣然公佈本集團截至2023年12月31日止年度經審核綜合業績，連同截至 2022年12月31日止年度之比較經審核數據。有關業績已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（倘文意另有所指）本集團。本公 告所載若干金額及百分比數據已因約整進行調整，或已約整至一個或兩個小 數位。任何表格、圖表或其他地方中總額與當中所列金額總和之間的任何差異 乃因約整所致。 | --- | --- | --- | |---------------------------------------|------------------------------ ...

智通财经APP获悉，微创机器人-B(02252)跌超3%，截至发稿，跌3.09%，报13.8港元，成交额584.78万 港元。 消息面上，微创机器人公布，预计2023年度净亏损不超过10.5亿人民币，相较上年度取得11.46亿人民 币。亏损减少主要因营业收入增长带来毛利增加；及焦核心研发项目，提升研发效率带来研发费用下 降。 此外，公司预计2023年度收入同比增长超过350%，该增长主要归因于集团产品图迈四臂腔镜手术机器 人、鸿鹄关节置换手术机器人、蜻蜓眼三维电子腹腔内窥镜全面推进商业化进程带来销售收入的持续增 长。 ...

AME IBC 微创机器人 D MEDBOT MEDIO MUNICIA 0 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微创医疗机器人(集团)股份有限公司 股票代碼：2252 (於中華人民共和國註冊成立的股份有限公司) 史期報告 2 0 2 3 目 錄 2 公司資料 財務摘要 | --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | 4 | | | | | 5 | | | | | 6 | | | | 公司概況 總裁報告 管理層討論及分析 企業管治及其他資料 獨立核數師報告 綜合損益表 綜合損益及其他全面收益表 綜合財務狀況表 綜合權益變動表 簡明綜合現金流量表 未經審核中期財務報告附註 釋義 9 28 38 40 41 42 44 46 47 61 公司資料 董事及監事 執行董事 何超博士（總裁） 非執行董事 孫洪斌先生（董事長） 孫欣先生 陳琛先生 獨立非執行董事 李明華博士 姚海嵩先生 梅永康 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上 海 微 創 醫 療 機 器 人（ 集 團 ）股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2023年6月30日止六個月之 中期業績公告 董 事 會 欣 然 公 佈 本集 團 截 至 2023 年 6 月 30 日 止 六 個 月 之 未 經 審 核 綜 合 中期 業 績 ， 連 同 截 至 2022年6月30日止六個月之比較數字，已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（ 倘文意另有所指 ）本集團。本公告所載若干金 額及百分比數據已因約整進行調整，或已約整至一個或兩個小數位。任何表格、圖表或其 他地方中總額與當中所列金額總和之間的任何差異乃因約整所致。 | --- | --- | --- | |---------------------- ...